---
title: "Obefazimod (ABX464) in Ulcerative colitis: Effects of other drugs"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Effects of other drugs. Topics: Fluvoxamine, a CYP1A2 inhibitor: obefazimod exposure in healthy participants (Part B); Fluvoxamine: exclusions from the pharmacokinetic analysis; Fluvoxamine: sponsor plain-language summary of results. 3 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Obefazimod

<a id="topic-2.1.2.9.1-1"></a>

### Fluvoxamine, a CYP1A2 inhibitor: obefazimod exposure in healthy participants (Part B)

| Parameter | Day 1, obefazimod 50 mg alone | Day 11, obefazimod 50 mg with fluvoxamine 100 mg |
| --- | --- | --- |
| Participants analyzed | “25” | “25” |
| Cmax, ng/mL, mean (SD) | “23.2(12.5)” | “33.4(19.0)” |
| AUC, h*ng/mL, mean (SD) | “55.2(25.7)” | “73.0(34.2)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.1-2"></a>

### Fluvoxamine: exclusions from the pharmacokinetic analysis

> “Of the 35 participants enrolled into Part B of the study, 9 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for a vomiting episode within 2 x median Tmax on either Day 1 or Day 11 and 1 participant was excluded as an early withdrawal from the study”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.1-3"></a>

### Fluvoxamine: sponsor plain-language summary of results

> “ABX464 may be metabolised in the same pathway as fluvoxamine, as the levels of ABX464 in the blood showed increases in the presence of fluvoxamine.”
> “With respect to the safety objectives of the study, it was determined ABX464 was considered to be safe and well tolerated at a 50 mg dose strength, both in the presence and absence of caffeine and fluvoxamine respectively.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
